Adaptimmune Therapeutics Plc (ADAPY) Stock Price & Analysis
Adaptimmune Therapeutics Plc (ADAPY) fell 3.57% to USD 0.03 as of June 10, 2026 at 05:03 UTC, according to Nexqual real-time market data.
ADAPY last closed at USD 0.03; the session ranged USD 0.03–0.03 on volume of 169,247 shares. Market capitalization is $7.16M, with a 52-week range of USD 0–0.36 (PNK). Source: Nexqual, June 10, 2026 at 05:03 UTC.
Key Statistics (as of June 10, 2026 at 05:03 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▼ 3.57% (down) |
| Previous Close | USD 0.03 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0 – 0.36 |
| Volume | 169,247 shares |
| Market Cap | $7.16M |
| Exchange | PNK |
Technical Analysis (ADAPY)
Nexqual's technical model rates ADAPY "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:03 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.82 (neutral) |
| vs SMA50 | Above (USD 0.01) |
| MACD | 0 (positive) |
Analyst Ratings (ADAPY)
Wall Street analysts rate ADAPY "None", per Nexqual as of June 10, 2026 at 05:03 UTC.
| Consensus Rating | None |
|---|
Earnings (ADAPY)
| Next Earnings Date | 2026-04-23 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.12 vs est -0.13 ▲ beat |
| 2025-03-31 | USD -0.18 vs est -0.17 ▼ miss |
| 2024-12-31 | USD -0.24 vs est -0.15 ▼ miss |
| 2024-09-30 | USD -0.01 vs est -0.18 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financials & Fundamentals (ADAPY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financial Health Score (ADAPY)
Nexqual rates Adaptimmune Therapeutics Plc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:03 UTC.
| Growth | Strong — Revenue +195% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (ADAPY)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 265.05M |
| Short % of Float | +14.34% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Leadership (ADAPY)
Adaptimmune Therapeutics Plc is led by Christopher James Hill ACA, BA (Hons) (age 45), CEO, CFO, Secretary & Director, per Nexqual as of June 10, 2026 at 05:03 UTC.
| CEO, CFO, Secretary & Director | Christopher James Hill ACA, BA (Hons) (age 45) |
|---|---|
| Senior Director of Corporate Communications | Dana Lynch |
| Vice President of Commercial Planning | Kimberly Freeman |
| Vice President of Medical Affairs | Laura Gunn |
From Adaptimmune Therapeutics Plc's Latest SEC 10-K Filing (filed 2025-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
- It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.
- The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Partnerships
- It has a strategic collaboration with Galápagos for a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galápagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; a collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
| CLLS | Cellectis S.A. | USD 2.99 | ▼ 2.29% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:03 UTC. This page is informational and not investment advice.